Know Cancer

forgot password

A Phase III, Prospective Randomised Comparison of Imatinib (STI571, Glivec/Gleevec) 400mg Daily Versus Dasatinib 100mg in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia

Phase 3
18 Years
Open (Enrolling)
Myeloid Leukemia, Chronic, Chronic Phase

Thank you

Trial Information

A Phase III, Prospective Randomised Comparison of Imatinib (STI571, Glivec/Gleevec) 400mg Daily Versus Dasatinib 100mg in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia

Inclusion Criteria:

1. Male or female patients 18 years or over.

2. Patients must have all of the following:

- be enrolled within 3 months of initial diagnosis of CML-CP (date of initial
diagnosis is the date of first cytogenetic analysis)

- cytogenetic confirmation of the Philadelphia chromosome or variants of (9;22)

- patients may have secondary chromosomal abnormalities in addition to the
Philadelphia chromosome.

- < 15% blasts in peripheral blood and bone marrow;

- < 30% blasts plus promyelocytes in peripheral blood and bone marrow;

- < 20% basophils in peripheral blood,

- 100 x 109/L platelets or greater

- no evidence of extramedullary leukaemic involvement, with the exception of the

3. Written voluntary informed consent.

Exclusion Criteria:

1. Patients with Ph-negative, BCR-ABL-positive, disease are NOT eligible for the study.

2. Any prior treatment for CML with: any tyrosine kinase inhibitor (eg imatinib,
dasatinib); busulphan; interferon-alpha; homoharringtonine; cytosine arabinoside; any
other investigational agents (hydroxycarbamide and anagrelide are the only drugs
permitted). NB patients will be ineligible for the study if they have received ANY
prior therapy with interferon-alpha or imatinib. NO exceptions.

3. Patients who received prior chemotherapy, including regimens used in peripheral blood
progenitor cells (PBPCs) mobilisation for haematopoietic progenitor-cell
transplantation. (It is allowable to collect unmobilised PBPCs at diagnosis.)

4. Patient who have had any form of prior haemopoietic stem cell transplant, either
autograft or allograft.

5. Patients with an ECOG Performance Status Score of 2 or less.

6. Patients with serum bilirubin, SGOT/AST, SGPT/ALT, or creatinine concentrations > 2.0
x the institutional upper limit of the normal range (IULN).

7. Patients with International normalized ratio (INR) or partial thromboplastin time
(PTT) > 1.5 x IULN, with the exception of patients on treatment with oral

8. Patients with uncontrolled medical disease such as diabetes mellitus, thyroid
dysfunction, neuropsychiatric disorders, infection, angina, or Grade 3/4 cardiac
problems as defined by the New York Heart Association Criteria.

9. Patients with known positivity for human immunodeficiency virus (HIV); baseline
testing for HIV is not required.

10. Patients who have undergone major surgery within 4 weeks of Study Day 1, or who have
not recovered from prior major surgery.

11. Patients who are:

- pregnant,

- breast feeding,

- of childbearing potential without a negative pregnancy test prior to Study Day
1, and

- male or female of childbearing potential unwilling to use barrier contraceptive
precautions throughout the trial (postmenopausal women must be amenorrheic for
at least 12 months to be considered of non-childbearing potential).

12. Patients with a history of another malignancy either currently or within the past
five years, with the exception of basal cell skin carcinoma or cervical carcinoma in

13. Patients with a history of non-compliance to medical regimens or who are considered
potentially unreliable.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

5-year event free survival

Outcome Description:

To compare 5-year event free survival between the 2 treatment arms. The study aim is to show superiority of the dasatinib arm over the imatinib 400mg arm.

Outcome Time Frame:

ongoing throughout study (5 years)

Safety Issue:


Principal Investigator

Stephen G O'Brien, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Newcastle University


United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study ID:




Start Date:

August 2008

Completion Date:

August 2017

Related Keywords:

  • Myeloid Leukemia, Chronic, Chronic Phase
  • Leukemia
  • Myeloid
  • Chronic
  • Chronic-Phase
  • CML
  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Leukemia, Myeloid, Chronic-Phase
  • Chronic Disease